Clinical Trials


Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients

The recruitment status of this study is unknown.

Verified October 2011 by Tel-Aviv Sourasky Medical Center

Tel-Aviv Sourasky Medical Center

SciGen, Israel

Information provided by (Responsible Party)
Tel-Aviv Sourasky Medical Center Identifier

First received: September 19, 2011
Last updated: October 5, 2011
Last Verified: October 2011
History of Changes


HBV vaccination is of paramount importance among HIV positive persons due to an increased risk of infection and disease progression. The most widely used ENGERIX B vaccine reaches a lower rate of vaccination (20-70%) among HIV positive vaccinees (compared to over 90% in the normal population). Sci-B-Vac is novel vaccine containing 3 antigens and is therefore more immunogenic (as opposed to one in ENGERIX B). Its use has been associated with higher and more rapid vaccination rates. Therefore, it has a theoretical advantage in HIV positive individuals.

Condition Intervention

Biological : Sci-B-Vac

Study Type: Interventional
Study Design: Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Efficiency of the Novel Hepatitis B Vaccine Sci-B-Vac in HIV Positive Patients, a Prospective Cohort Study

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures

  • HBV immunization rate after 1, 2 and 3rd dose of Sci-B-Vac [ Time Frame: 12 months ]
    HBV Surface antibodies will be obtained one month after each Sci-B-Vac dose for each vaccinee. Rate and rapidity of immunization will be measured.

Estimated Enrollment: 100
Study Start Date: November 2011
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Sci-B-Vac
The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
Biological: Sci-B-Vac

10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly

Detailed Description:

A cohort of 100 HIV positive, HBV negative individuals who have not been vaccinated against HBV before will be prospectively given 3 doses of Sci-B-Vac at 0, 1 and 6 months. HBV antibodies will be checked one month after every dose given.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • HBV negative
  • HIV positive individuals
  • Above the age of 18
  • Treated at the TASMC Aids clinic, who have signed and informed consent and have never been vaccinated against HBV before

Exclusion Criteria:
  • Pregnant women
  • HBV positivity
  • Previous HBV vaccination

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01437475


Dan Turner
Tel Aviv, Israel, 64239
Contact: Dan Turner, MD    9725266656

Sponsors and Collaborators

Tel-Aviv Sourasky Medical Center
SciGen, Israel


Study Chair: Dan Turner, MD Tel-Aviv Sourasky Medical Center
Principal Investigator: Danny Alon, MD Tel-Aviv Sourasky Medical Center
More Information

More Information

Responsible Party: Tel-Aviv Sourasky Medical Center Identifier: NCT01437475   History of Changes  
Other Study ID Numbers: TASMC-11-DA-0277-CITL  
Study First Received: September 19, 2011  
Last Updated: October 5, 2011  

Keywords provided by Tel-Aviv Sourasky Medical Center:

HBV Immunization rate among HIV positive individuals

Additional relevant MeSH terms:
Hepatitis B
HIV Seropositivity processed this data on June 01, 2020
This information is provided by